Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

2015686 citationsJournal Articlehybrid Open Access

Authors

Scott Kopetz · The University of Texas MD Anderson Cancer Center

Jayesh Desai · The University of Texas MD Anderson Cancer Center

Emily Chan · The University of Texas MD Anderson Cancer Center

J. Randolph Hecht · The University of Texas MD Anderson Cancer Center

Peter J. O’Dwyer · The University of Texas MD Anderson Cancer Center

Dipen M. Maru · The University of Texas MD Anderson Cancer Center

Abstract

In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC. Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.

Topics & Keywords

Melanoma and MAPK Pathways Colorectal Cancer Treatments and Studies Cutaneous Melanoma Detection and Management

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 34, pp. 4032-4038

DOI: 10.1200/jco.2015.63.2497

Field-Weighted Citation Impact: 31.78